BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28670108)

  • 21. 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis.
    Salvatore B; Fonti R; De Renzo A; Pellegrino S; Ferrara IL; Mainolfi CG; Marano L; Selleri C; Pane F; Del Vecchio S; Pace L
    Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):219-225. PubMed ID: 29697219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical usefulness of FDG-PET/CT for the evaluation of various types of adult T-cell leukemia.
    Nakachi S; Okada M; Morishima S; Agarie Y; Kitamura S; Uchibori S; Tomori S; Hanashiro T; Shimabukuro N; Tamaki K; Tedokon I; Morichika K; Nishi Y; Tomoyose T; Karube K; Fukushima T; Murayama S; Masuzaki H
    Hematology; 2017 Oct; 22(9):536-543. PubMed ID: 28397608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma.
    Mistry V; Scott JR; Wang TY; Mollee P; Miles KA; Law WP; Hapgood G
    Cancer Imaging; 2023 Jan; 23(1):11. PubMed ID: 36694244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods.
    Moon SH; Cho SK; Kim WS; Kim SJ; Chan Ahn Y; Choe YS; Lee KH; Kim BT; Choi JY
    J Nucl Med; 2013 Jul; 54(7):1039-44. PubMed ID: 23658217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results.
    Christlieb SB; Strandholdt CN; Olsen BB; Mylam KJ; Larsen TS; Nielsen AL; Rohde M; Gerke O; Olsen KE; Møller MB; Kristensen BW; Abildgaard N; Alavi A; Høilund-Carlsen PF
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1824-36. PubMed ID: 27102266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revised staging system for malignant lymphoma based on the Lugano classification.
    Munakata W; Terauchi T; Maruyama D; Nagai H
    Jpn J Clin Oncol; 2019 Oct; 49(10):895-900. PubMed ID: 31504700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients.
    Abdulqadhr G; Molin D; Aström G; Suurküla M; Johansson L; Hagberg H; Ahlström H
    Acta Radiol; 2011 Mar; 52(2):173-80. PubMed ID: 21498346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual FDG uptake of primary thyroid lymphoma after treatment may overestimate residual lymphoma.
    Fujii H; Nakadate M; Tanaka H; Harata N; Oota S; Isogai J; Yoshida K
    Ann Nucl Med; 2016 Dec; 30(10):756-759. PubMed ID: 27614754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.
    Zanoni L; Broccoli A; Lambertini A; Pellegrini C; Stefoni V; Lodi F; Fonti C; Nanni C; Zinzani PL; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1661-1671. PubMed ID: 31102000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.
    Gómez León N; Delgado-Bolton RC; Del Campo Del Val L; Cabezas B; Arranz R; García M; Cannata J; González Ortega S; Pérez Sáez MÁ; López-Botet B; Rodríguez-Vigil B; Mateo M; Colletti PM; Rubello D; Carreras JL
    Clin Nucl Med; 2017 Aug; 42(8):595-602. PubMed ID: 28604477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard.
    Littooij AS; Kwee TC; Barber I; Granata C; Vermoolen MA; Enríquez G; Zsíros J; Soh SY; de Keizer B; Beek FJ; Hobbelink MG; Bierings MB; Stoker J; Nievelstein RA
    Eur Radiol; 2014 May; 24(5):1153-65. PubMed ID: 24563179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUV
    Fan Y; Zhang Y; Yang Z; Ying Z; Zhou N; Liu C; Song Y; Zhu J; Wang X
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28535082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging.
    Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Staudenherz A; Senn D; Raderer M; Weber M; Simonitsch-Klupp I; Mayerhoefer ME
    PLoS One; 2016; 11(10):e0164118. PubMed ID: 27723817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
    Nanni C; Versari A; Chauvie S; Bertone E; Bianchi A; Rensi M; Bellò M; Gallamini A; Patriarca F; Gay F; Gamberi B; Ghedini P; Cavo M; Fanti S; Zamagni E
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):712-719. PubMed ID: 29270787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of
    Marchetti L; Perrucci L; Pellegrino F; Baroni L; Merlo A; Tilli M; Rambaldi I; Maietti E; Carnevale A; Bartolomei M; Giganti M
    J Nucl Med; 2021 Oct; 62(10):1372-1379. PubMed ID: 33712534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas.
    Maccioni F; Alfieri G; Assanto GM; Mattone M; Gentiloni Silveri G; Viola F; De Maio A; Frantellizzi V; Di Rocco A; De Vincentis G; Pulsoni A; Martelli M; Catalano C
    Radiol Med; 2023 May; 128(5):556-564. PubMed ID: 37145214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
    Basu S; Li G; Bural G; Alavi A
    Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.